Immunotherapy and cirrhosis – expanding Child-Pugh boundaries in liver cancer

Immunotherapy has historically been restricted to HCC patients with well-preserved liver function, based upon safety and efficacy data established in clinical trial populations. While an immune-suppressive microenvironment coupled with comorbid cirrhosis may contribute to poorer outcomes, a subset of patients with worse degrees of liver function achieves significant clinical benefit from combination immunotherapy.